ISDA

Entry Detail

PDB ID:

7A4B

Keywords:

Title:

Crystal structure of human protein kinase CK2alpha (CSNK2A1 gene product) in complex with the ATP-competitive inhibitor 5,6-dibromo-1H-triazolo[4,5-b]pyridine

Biological Source:

Source Organism:

Homo sapiens

Host Organism:

Escherichia coli

PDB Version:

Deposition Date:

2020-08-19

Release Date:

2020-12-09

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.06 Å

R-Value Free:

0.22

R-Value Work:

0.19

R-Value Observed:

0.19

Space Group:

P 43 21 2

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:Casein kinase II subunit alpha
Chain IDs:A, B
Chain Length:335
Number of Molecules:2
Biological Source:Homo sapiens

UniProt ID:P68400 Pfam ID:PF00069 EC:2.7.11.1

Ligand Molecules

GOL

QXW

SO4

Primary Citation

Synthesis, biological properties and structural study of new halogenated azolo[4,5-b]pyridines as inhibitors of CK2 kinase.

Chojnacki, K, Lindenblatt, D, Winska, P, Wielechowska, M, Toelzer, C, Niefind, K, Bretner, M, Chojnacki, K, Winska, P, Wielechowska, M, Lukowska-Chojnacka, E, Toelzer, C, Niefind, K, Bretner, M, Lindenblatt, D, Nickelsen, A, Applegate, V.M, Hochscherf, J, Witulski, B, Bouaziz, Z, Marminon, C, Bretner, M, Le Borgne, M, Jose, J, Niefind, K, Lindenblatt, D, Nickelsen, A, Applegate, V.M, Jose, J, Niefind, K.Show

Bioorg.Chem. 106 104502 104502 (2021)

PMID: 33317841 DOI: 10.1016/j.bioorg.2020.104502

Abstact

The new halogenated 1H-triazolo[4,5-b]pyridines and 1H-imidazo[4,5-b]pyridines were synthesised as analogues of known CK2 inhibitors: 4,5,6,7-tetrabromo-1H-benzotriazole (TBBt) and 4,5,6,7-tetrabromo-1H-benzimidazole (TBBi). Their influence on the activity of recombinant human CK2α, CK2α' and PIM1 kinases was determined. The most active inhibitors were di- and trihalogenated 1H-triazolo[4,5-b]pyridines (4a, 5a and 10a) with IC50 values 2.56, 3.82 and 3.26 μM respectively for CK2α. Furthermore, effect on viability of cancer cell lines MCF-7 (human breast adenocarcinoma) and CCRF-CEM (T lymphoblast leukemia) of all final compounds was evaluated. Finally, three crystal structures of complexes of CK2α1-335 with inhibitors 4a, 5a and 10a were obtained. In addition, new protocol was used to obtain high-resolution crystal structures of CK2α'Cys336Ser in complex with four inhibitors (4a, 5a, 5b, 10a).

Legend

Protein

Chemical

Disease

Primary Citation of related structures